INTRODUCTION
============

Osteoporosis and coronary heart disease (CHD) are 2 primary diseases that result in substantial morbidity and mortality in older people. Osteoporosis is characterized by low bone mass, structural deterioration of bone tissue, and compromised bone strength predisposing to increased susceptibility to fracture.^[@R1]^ The bone is a dynamic tissue that is continually being remodeled following 2 opposite and coordinated processes. Bone resorbing cells, called osteoclasts, transiently break down old bone as other bone-forming cells, known as osteoblasts, are replacing it with new tissue. Osteoblastic cells assure bone formation and mineralization by secreting bone matrix components (type I collagen and noncollagenous proteins) and play a central role in regulating bone resorption by providing essential factors such as the macrophage colony-stimulating factor and the receptor activator of nuclear factor Kappa-B ligand (RANKL) for differentiating osteoclasts.^[@R2],[@R3]^ Altered osteoblastic proliferation, differentiation, secretory functions, or apoptosis rate compromise the maintenance of bone remodeling equilibrium, resulting in low bone mass or osteoporosis.

CHD, the leading cause of death worldwide, is caused by atherothrombotic vascular occlusion, which leads to progressive ischemia of the heart muscle (stable or unstable angina), acute myocardial infarction and sudden cardiac arrest.^[@R4]--[@R6]^ Atherosclerosis, the primary cause of CHD, is an inflammatory disease of the wall of large- and medium-sized arteries, in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial tree.^[@R7],[@R8]^ Previous studies have indicated that the initial step in CHD development is subendothelial accumulation of low-density lipoprotein (LDL) caused by endothelial dysfunction and structure alterations.^[@R5],[@R8]--[@R11]^ The formation of atheromatous plaques orchestrated by a complex interplay of various cell types, such as endothelial cells, vascular smooth muscle cells, and macrophages, narrows or obstructs the coronary arteries, causing ischemia of the myocardium.^[@R5],[@R8]^

Previous investigations have suggested that osteoporosis and CHD have shared risk factors, such as hypertension, diabetes, smoking, alcohol abuse, and a low level of physical activity, and that the close relationship is independent of age.^[@R12],[@R13]^ Moreover, low bone mineral density (BMD) has been related to increased cardiovascular mortality and morbidity.^[@R14]^ Potential links underlying both diseases may be related to the calcification process that is involved in atherosclerosis and bone mineralization.^[@R13],[@R15]^ Mineralization is of particular interest because numerous noncollagenous bone-related proteins mediating bone resorption have also been implicated in calcification and ossification in the vascular intima.^[@R16]--[@R18]^

Despite the possible inverse association between low bone density and cardiovascular events, there were few studies to address the association of osteoporosis with CHD events in Asian population and some studies in Taiwan showed no association between osteoporosis and subclinical CHD.^[@R19]^ The risk of CHD differs between Asian and Caucasian populations; however, most previous studies in this field have relied on Caucasian postmenopausal women and have rarely targeted an Asian population. Therefore, we used the longitudinal population-based database of the Taiwan\'s National Health Insurance (NHI) program to assess the association between osteoporosis and CHD in an Asian population.

METHODS
=======

Study Design
------------

The NHI program is a universal healthcare system with coverage of over 99% of the entire population of Taiwan. The program was established in 1995 and was consolidated from 13 insurance programs covering all necessary medical expense including medication. Data for this retrospective cohort study were retrieved from Longitudinal Health Insurance Database (LHID), which consists of the claims data of 1,000,000 people randomly sampled from the 2000 registry for beneficiaries (n = 23.72 million) of the NHI program (<http://www.nhi.gov.tw/english/index.aspx>). The LHID consists of deidentified secondary data including outpatient and inpatient setting, and all of the aforementioned randomly sampled patients were followed to the year 2011. The International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) was used to identify health statuses. The study was approved by the Institutional Review Board of China Medical University (CMU-REC-101-012).

Sampled Patients
----------------

From 2000 to 2010, we identified patients aged 45 or more with a diagnosis of osteoporosis (ICD-9-CM codes 733.0 and 733.1) in the LHID as the osteoporosis cohort. The date of osteoporosis diagnosis was defined as the index date. We excluded patients with a diagnosis of CHD (ICD-9-CM codes 410--414) before the index date and those with incomplete age, sex, or medical record information. The look-back period is at least 4 years because the LHID is available since 1996. NHI database covers a highly representative sample of Taiwan\'s general population because the reimbursement policy is universal and operated by a single-buyer, the government in Taiwan. All insurance claims should be scrutinized by medical reimbursement specialists and peer review according to the standard and clinical diagnosed criteria such as dual-energy X-ray absorptiometry for osteoporosis and cardiac imaging (radionuclide myocardial perfusion imaging or coronary angiography) for CHD. Therefore, the diagnoses of osteoporosis and CHD in this study were highly reliable. The patients in the comparison cohort without a diagnosis of osteoporosis, with the same exclusion criteria, were randomly selected from LHID beneficiaries and frequency matched according to age (in 5-year bands), sex, and the year of index date at a 1:1 ratio.

Baseline Variables
------------------

We obtained baseline variables, including age, sex, comorbidities of diabetes (ICD-9-CM codes 250), hypertension (ICD-9-CM codes 401--405), hyperlipidemia (ICD-9-CM codes 272), chronic kidney disease (CKD) (ICD-9-CM codes 580--589), chronic obstructive pulmonary disease (COPD) (ICD-9-CM codes 491, 492, and 496), asthma (ICD-9-CM code 493), alcohol-related illnesses (ICD-9-CM codes 291, 303, 305, 571.0, 571.1, 571.2, and 571.3), and estrogen supplement (women only) and bisphosphonate medication that were ever used.

Outcome Measurement
-------------------

Both the osteoporosis and comparison cohorts were followed-up from the index date until a new diagnosis of CHD (ICD-9-CM 410--414) was made or until the patients were censored because of loss to follow-up, withdrawal from the insurance system, or the end of 2011, whichever occurred first.

Statistical Analysis
--------------------

Distribution of age, sex, comorbidities, and medications were compared between the osteoporosis cohort and the comparison cohort, and were examined using the chi-square test for categorical variables and the *t* test for continuous variables. For estimating the cumulative incidence of CHD in osteoporosis patients and comparison patients, we performed survival analysis by using the Kaplan--Meier method, with significance based on the log-rank test. The overall and age-, sex-, and comorbidity-specific incidence densities of CHD were measured for each cohort. Univariate and multivariate Cox proportion hazard regression models were used to examine the effect of osteoporosis on the risk for CHD, shown as a hazard ratio (HR) with a 95% confidence interval (CI). The confounders including age, sex, and comorbidities of diabetes, hypertension, hyperlipidemia, CKD, COPD, asthma, and alcohol-related illnesses and estrogen supplement were adjusted in the multivariate analysis. Osteoporotic fracture was evaluated for the risk of CHD in the subgroup analysis. The effect of medications on the risk of CHD in all osteoporosis patients was analyzed. All analyses were performed using SAS statistical software for Windows (Version 9.2; SAS Institute, Inc., Cary, NC), and the significance level was set to less than .05.

RESULTS
=======

Our study comprised a cohort of 19,456 patients with osteoporosis and a comparison cohort of 19,456 patients (Table [1](#T1){ref-type="table"}). Patients were mainly aged 65 or older (45.7%) and women accounted for 80.2%. The mean age of the osteoporosis cohort was 64.0 years (standard deviation \[SD\] = 11.4) and that of the comparison cohort was 63.2 years (SD = 11.7). Compared with the comparison cohort, the osteoporosis cohort exhibited a significantly higher rate of comorbidities of diabetes, hypertension, hyperlipidemia, CKD, COPD, asthma and alcohol-related illness, and estrogen supplement (all *P* \< 0.001).

###### 

Comparison of Baseline Characteristics Between Patients With and Without Osteoporosis
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Figure [1](#F1){ref-type="fig"} shows the cumulative incidence curves of CHD for patients with or without osteoporosis, with the osteoporosis cohort significantly higher than the comparison cohort (log-rank test *P* \< 0.001). The overall incidence of CHD (per 1000 person-years) was 23.5 for the osteoporosis cohort and 16.7 for the comparison cohort, with a mean follow-up of 6.54 and 6.63 years, respectively (Table [2](#T2){ref-type="table"}). After adjusting for age, sex, comorbidities, and estrogen supplement, the HR for developing CHD during the follow-up years was 1.30 (95% CI, 1.23--1.38) for the osteoporosis cohort. The incidence of CHD increased with age in both cohorts, whereas the relative risk was greatest in the youngest age-specific group (age 45--54 years) in the osteoporosis cohort compared with that in the comparison cohort (adjusted HR = 1.49; 95% CI, 1.18--1.87). The incidence rate of CHD was greater in men than in women in both cohorts. The adjusted HR of CHD was greater in the osteoporosis cohort compared with the comparison cohort for both women and men (adjusted HR = 1.33; 95% CI, 1.25--1.41 and adjusted HR = 1.19; 95% CI, 1.04--1.35, respectively). The incidence of CHD increased with comorbidities in both cohorts. For patients without comorbidities, the risk of CHD was 1.56-fold greater in the osteoporosis cohort than in the comparison cohort (95% CI, 1.40--1.74).

![Cumulative incidence of coronary heart disease for patients with (dashed line) or without (solid line) osteoporosis.](medi-94-e1146-g002){#F1}

###### 

Risk of Coronary Heart Disease in Relation to Osteoporosis and After Stratification by Age, Sex, or Comorbidity
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The incidences and HRs of CHD were further analyzed according to subgroup of osteoporosis (Table [3](#T3){ref-type="table"}). Patients with osteoporosis-related fracture (pathologic fracture) were not significantly related to developing CHD compared with those in the comparison group, with an adjusted HR of 0.97 (95% CI, 0.75--1.25). Patients with osteoporosis who received bisphosphonates or both bisphosphonates and estrogen exhibited a significantly lower risk of CHD (adjusted HR = 0.37 and 0.23) compared with those without either of these 2 medications (Table [4](#T4){ref-type="table"}).
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Comparison of Risk of Coronary Heart Disease by Subgroups of the Osteoporosis
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###### 

Risk of Coronary Heart Disease in Osteoporosis Patients Receiving Bisphosphonate or Estrogen
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DISCUSSION
==========

The results of this population-based cohort study suggest that patients with osteoporosis have higher risk of CHD than those without osteoporosis. Patients who have osteoporosis and have received treatment with bisphosphonates have a significantly lower risk for CHD than are those without treatment. Our findings suggest that osteoporosis is significantly associated with the risk of CHD in an Asian population.

Farhat et al^[@R14]^ studied the incidence of cardiovascular disease in a prospective study and found a reverse association between BMD and cardiovascular disease in black women and Caucasian men. In a selective estrogen-receptor modulator trial, osteoporosis showed a 3.9-fold increased risk of cardiovascular incidence compared with low bone mass in postmenopausal women.^[@R20]^ A retrospective analysis compared dual-energy X-ray absorptiometry determined BMD and angiographically determined CHD performed within a 12-month period in a population predominantly composed of Caucasian women, showing that osteoporosis is an independent risk factor for CHD.^[@R21]^ Moreover, osteoporosis was also reported with increased risk of morbidity and mortality caused by cardiovascular diseases.^[@R22]--[@R25]^ These studies have suggested a positive association between osteoporosis and the development of cardiovascular disease independent of age and other traditional cardiovascular risk factors.

Potential mechanisms that link osteoporosis to atherosclerosis include bone and vascular mineralization, estrogen deficiency, elevated plasma homocysteine concentrations, lipid oxidation, and ongoing inflammatory processes.^[@R13]^ In particular, calcium deposition and atherosclerosis have been linked to the connection between osteoporosis and cardiovascular diseases.^[@R26]--[@R28]^ Lower BMD is significantly associated with greater coronary and aortic calcium and calcified atherosclerosis.^[@R25],[@R29]^ Biological evidence, including inflammatory cytokines, endogenous sex hormones, oxidized lipids, and vitamin D, suggest that calcified atherosclerosis is not a passive deposition, but a highly organized process that is regulated by mechanisms similar to those involved in bone mineralization.^[@R12],[@R30]^ Calcified atherosclerosis is also considered to be a predicted marker of the risk for a coronary artery event.^[@R31],[@R32]^ Besides, lipid accumulation has been observed in osteoporotic and aging bone. The LDL particles and LDL-associated apolipoprotein-B have been reported to have a positive association with osteoporosis.^[@R33]^ Osteoclast survival, activation, and differentiation are stimulated by the receptor activator of nuclear factor Kappa-B ligand (RANKL) and counteracted by osteoprotegerin (OPG).^[@R34],[@R35]^ RANKL is localized at the osteoblast and stroma cell membrane, whereas OPG is secreted by osteoblasts. The oxidized LDL particles alter osteoblastic cell proliferation, migration, and apoptosis rate through oxidative stress, and therefore may contribute to alteration of bone metabolism equilibrium.^[@R2]^ These results elucidate the crucial role of vascular calcification in osteoporotic patient and the process of atherosclerosis.

Women with osteoporosis were associated with a greater relative risk for CHD than were those without osteoporosis in our study. Loss of estrogen protection increases the risk of atherogenesis, and an average of 10-year-earlier development of osteoporosis for menopausal women may underline the differing effects of sex hormones on the risk inequality between the sexes.^[@R36]^ Estrogen can prevent osteoporosis by suppressing bone resorption through RANKL and the OPG system on osteoclasts,^[@R37]^ and has been suggested the dominant sex steroid regulating bone resorption in aging men.^[@R38]^ Although estrogen exerts sex differences on bone metabolism, estrogen deficiency is documented to increase the risk of osteoporosis and is associated with greater risk of cardiovascular diseases.

Previous studies have suggested antiatherosclerotic effects of bisphosphonates, including inhibiting inflammation, intimal hyperplasia, cholesterol synthesis, and vascular calcification.^[@R39],[@R40]^ Nitrogen-containing bisphosphonates can act on the cholesterol biosynthesis pathway and exert effects on lipids metabolism in postmenopausal women with osteoporosis.^[@R16]^ Chronic intravenous therapy with neridronate has been shown to reduce LDL-C and apolipoprotein B and to increase high density lipoprotein C.^[@R41]^ Alendronate significantly reduced intima-media thickness and altered the lipid profile of the carotid artery among postmenopausal women during a 1-year follow-up.^[@R42]^ An observational study on an Asian population also showed a lower incidence of acute myocardial infarction in bisphosphonate users in a 2-year follow-up.^[@R43]^ Of note, patients with osteoporotic (pathological) fractures showed a less CHD risk in our study (Table [3](#T3){ref-type="table"}). The potential dual effects of bisphosphonates, which were given to more patients in osteoporotic fracture (15.2% vs. 26.6%), might have partially explained the reduced risk for CHD although the sample size is relatively small.

Certain limitations of this study should be noted. First, NHI database does not provide information on smoking, body mass index, socioeconomic status, and physical activity, which are all potential confounding factors for this study. Second, the diagnoses of osteoporosis and CHD relied on NHI records. Because the NHI database does not provide personal information about BMD and coronary artery conditions, we were unable to ascertain and assess their severity. Third, lack of information on medication compliance was inherent in this registry database study; therefore, the medication effect may be underestimated. Fourth, despite our meticulous study design in which we adequately controlled the confounding factors, data derived from a retrospective cohort study are generally limited by potential selection bias, as well as residual confounding by using other cardiovascular medications. However, even with these limitations, the present study provides valuable information regarding the association between osteoporosis and CHD risk.

In conclusion, in a nation-wide Asian population, osteoporosis was associated with a 1.3-fold risk of incident CHD and the treatment with bisphosphonate for osteoporosis was associated with lower risk of CHD. The relative risk association with CHD is higher in women with osteoporosis. Clinicians should be aware of the close association between these 2 diseases. A CHD risk assessment allows for early identification of CHD and prompts therapeutic or preventive interventions to lower cardiovascular mobility in patients with osteoporosis.

Abbreviations: BMD = bone mineral density, CHD = coronary heart disease, CKD = chronic kidney disease, COPD = chronic obstructive pulmonary disease, LDL = low-density lipoprotein, LHID = Longitudinal Health Insurance Database, OPG = osteoprotegerin, RANKL = receptor activator of nuclear factor Kappa-B ligand.
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